Patient-specific neoantigen-human leukocyte antigen complex (NeoAg-HLA complex)

Patient-specific neoantigen peptides bound to HLA class I and class II molecules are unique molecular targets formed by the presentation of mutated protein fragments on the surface of cells. These neoantigens result from somatic mutations—such as non-synonymous single nucleotide variants (SNVs), insertions/deletions (indels), or gene fusions—that occur exclusively within the tumor genome (PubMed: 29735922). Because these peptides are not expressed in normal tissues, they are highly immunogenic and less likely to be subject to central thymic tolerance, making them ideal targets for precision immunotherapy (PubMed: 31048554). On antigen-presenting cells (APCs), these complexes are crucial for the priming of naive T-cells; HLA class I complexes interact with CD8+ T-cells, while HLA class II complexes interact with CD4+ T-cells (StatPearls: MHC). Therapeutic interventions, including personalized cancer vaccines and adoptive T-cell receptor (TCR) therapies, aim to prime or expand the patient's own T-cells to recognize these specific HLA-bound complexes. This approach facilitates a targeted immune attack against the malignancy while sparing healthy cells, though it requires sophisticated bioinformatics and rapid manufacturing to address the unique mutational profile of each patient (NIH: National Cancer Institute).

Other names

Tumor-specific neoantigen-MHC complexNeoepitope-HLA complexPersonalized neoantigen peptidesMHC-restricted tumor neoantigensTSA-HLA complex

Induction of de novo T-cell responses or expansion of existing neoantigen-specific CD4+ and CD8+ T-cells that recognize and eliminate tumor cells expressing the specific peptide-HLA complex.